[1] Lin GW, Wang JY, Ge JB. Practice of Internal Medicine. Beijing: People’s Medical Publishing House; 2017. 170.
[2] World Health Organization International Agency for Research on Cancer: Latest global cancer data: Cancer burden rises to 19.29 million new cases and 9.96 million cancer deaths in 2020
[3] Zhang J, Wang S, Meng FJ, Yan YJ, Wang B, Guan ZY. Research progress of glutathione peroxidase in tumor. Chinese Journal of Cancer 2019; 38: 282-287.
[4] Jiang YF, Qiu BX, Pang BY, Zhang YF. Research progress on the relationship between GPX3 and tumor and its mechanism. Guangdong Medical Journal 2018; 39: 258-260+265.
[5] Kalatskaya I. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. Ann N Y Acad Sci 2016; 1381: 74–91. https://doi.org/10.1111/nyas.13134
[6] Fujiwara S, Nagai H, Jimbo H, Jimbo N, Tanaka T, Inoie M, et al. Gene Expression and Methylation Analysis in Melanomas and Melanocytes from the Same Patient: Loss of NPM2 Expression Is a Potential Immunohistochemical Marker for Melanoma. Front Oncol 2019; 8: 675. https://doi.org/10.3389/fonc.2018.00675
[7] Hughes DJ, Kunická T, Schomburg L, Liška V, Swan N, Souček P. Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer. Nutrients 2018; 10: 1812. https://doi.org/10.3390/nu10111812
[8] Zhou C, Pan R, Li B, Huang T, Zhao J, Ying J, et al. GPX3 hypermethylation in gastric cancer and its prognostic value in patients aged over 60. Future Oncol 2019; 15: 1279–1289. https://doi.org/10.2217/fon-2018-0674
[9] Worley BL, Kim YS, Mardini J, Zaman R, Leon KE, Vallur PG, et al. GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment. Redox Biol 2019; 25: 101051. https://doi.org/10.1016/j.redox.2018.11.009
[10] Shen SX (2020) Analysis of the expression characteristics of pepsinogen C gene in pan-cancer and its regulatory mechanism. [dissertation/master’s thesis]. [Liao Ning]: China Medical University.
[11] Zhang K, Wang H. Cancer Genome Atlas Pan-cancer Analysis Project. Zhongguo Fei Ai Za Zhi 2015; 18:219-23. https://doi.org/10.3779/j.issn.1009-3419.2015.04.02
[12] Ye W, Luo C, Liu F, Liu Z, Chen F. CD96 Correlates with Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis. Front Oncol 2021; 11: 634617. https://doi.org/10.3389/fonc.2021.634617
[13] Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019; 47: W556-W560. https://doi.org/10.1093/nar/gkz430
[14] Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun 2019; 10: 5679. https://doi.org/10.1038/s41467-019-13528-0
[15] Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y, et al. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics 2020; 112: 3958-3967. https://doi.org/10.1016/j.ygeno.2020.06.044
[16] Ju Q, Li XM, Zhang H, Zhao YJ. BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis. Front Mol Biosci 2020; 7: 573619. https://doi.org/10.3389/fmolb.2020.573619
[17] Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity 2018; 48: 812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023
[18] Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol 2017; 2017: PO.17.00073. https://doi.org/10.1200/PO.17.00073
[19] Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, et al. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Front Immunol 2019; 10: 6. https://doi.org/10.3389/fimmu.2019.00006
[20] Wang Z, Gao L, Guo X, Feng C, Lian W, Deng K, et al. Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. Aging (Albany NY) 2019; 11: 12246-12269. https://doi.org/10.18632/aging.102566
[21] Chen L, Long C, Liu J, Duan X, Xiang Z. Prognostic nomograms to predict overall survival and cancer-specific survival in patients with pelvic chondrosarcoma. Cancer Med 2019; 8: 5438-5449. https://doi.org/10.1002/cam4.2452
[22] Chang QH, Mao T, Tao Y, Dong T, Tang XX, Ge GH, et al. Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma. Aging (Albany NY) 2021; 13:11096-11119. https://doi.org/10.18632/aging.202765
[23] Chen M, Zhang S, Nie Z, Wen X, Gao Y. Identification of an Autophagy-Related Prognostic Signature for Clear Cell Renal Cell Carcinoma. Front Oncol 2020;10: 873. https://doi.org/10.3389/fonc.2020.00873
[24] Saelee P, Pongtheerat T, Sophonnithiprasert T. Reduced Expression of GPX3 in Breast Cancer Patients in Correlation with Clinical Significance. Glob Med Genet 2020; 7: 87-91. https://doi.org/10.1055/s-0040-1722170
[25] Lou W, Ding B, Wang S, Fu P. Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro. Cancer Cell Int 2020; 20: 378. https://doi.org/10.1186/s12935-020-01466-7
[26] Noci S, Dugo M, Bertola F, Melotti F, Vannelli A, Dragani TA, et al. A subset of genetic susceptibility variants for colorectal cancer also has prognostic value. Pharmacogenomics J 2016; 16: 173-9. https://doi.org/10.1038/tpj.2015.35
[27] Li HL, Yu W, Chen YT, Li J. Changes of serum Gal-1 and GPX3 expression in patients with thyroid cancer and their relationship with disease severity 2020; 22: 191-193.
[28] Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective response and delayed toxicities of refractory advanced diffuse large B cell lymphoma treated by CD20 directed chimeric antigen receptor modified T cells. Clin Immunol 2014; 155: 160-175. https://doi.org/10.1016/j.clim.2014.10.002
[29] Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65. https://doi.org/10.1016/j.cca.2013.05.002
[30] An BC, Choi YD, Oh IJ, Kim JH, Park JI, Lee SW. GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines. PLoS One 2018; 13: e0204170. https://doi.org/10.1371/journal.pone.0204170
[31] Cai M, Sikong Y, Wang Q, Zhu S, Pang F, Cui X. Gpx3 prevents migration and invasion in gastric cancer by targeting NFкB/Wnt5a/JNK signaling. Int J Clin Exp Pathol 2019; 12:1194-1203.
[32] Chang C, Worley BL, Phaëton R, Hempel N. Extracellular Glutathione Peroxidase GPx3 and Its Role in Cancer. Cancers (Basel) 2020; 12: 2197. https://doi.org/10.3390/cancers12082197
[33] Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene 2018; 37:5435-5450. https://doi.org/10.1038/s41388-018-0315-z
[34] Lee HJ, Do JH, Bae S, Yang S, Zhang X, Lee A, et al. Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. Med Oncol 2011;28 Suppl 1: S522-7. https://doi.org/10.1007/s12032-010-9659-0
[35] Pelosof L, Yerram S, Armstrong T, Chu N, Danilova L, Yanagisawa B, et al. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics 2017; 12: 540-550. https://doi.org/10.1080/15592294.2016.1265711